Incysus Therapeutics to Present at the 2020 BIO CEO & Investor Conference
07 févr. 2020 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics to Present at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting
21 nov. 2019 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics to Present at the 2019 Bio Investor Forum
22 oct. 2019 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Lexington-Based NX Development Corp (NXDC) Announces Baptist Health Lexington is First Hospital in Kentucky to Use Breakthrough Imaging Agent for Brain Tumor Visualization
03 oct. 2019 12h58 HE
|
NX Development Corp.
Lexington, KY, Oct. 03, 2019 (GLOBE NEWSWIRE) -- NX Development Corp (NXDC), a life sciences company based in Lexington, KY, today announced Baptist Health Lexington is the first hospital in state...
Incysus Therapeutics to Present at the BioCentury NewsMakers in the Biotech Industry Conference
04 sept. 2019 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Synchronicity Pharma Highlights New Research Demonstrating Beneficial Effects of Modulating Core Clock Proteins in Glioblastoma Stem Cells
27 août 2019 09h00 HE
|
Synchronicity Pharma
SAN FRANCISCO, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Synchronicity Pharma (“Synchronicity”), a clinical-stage company focused on therapeutic translation of circadian clock biology, today announced the...
VBI Vaccines Announces Dosing of First Recurrent GBM Patient in Part B of Ongoing Phase 1/2a Study of VBI-1901
29 juil. 2019 08h00 HE
|
VBI Vaccines, Inc.
— Part B of the study, a subsequent extension of the optimal dose from Part A, to enroll 10 first-recurrent GBM patients— Initial immunologic data from Part B expected around year-end 2019— Expanded...
Incysus Therapeutics Appoints Rozanna Yaing As Senior Vice President, Quality And Regulatory Affairs
02 juil. 2019 08h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, July 02, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics Announces Publication of U.S. Patent for Drug Resistant Immunotherapy (DRI) Technology
19 juin 2019 08h00 HE
|
Incysus Therapeutics, Inc.
US Patent and Trademark Office Issues U.S. Patent Covering Drug Resistant Immunotherapy (DRI) TechnologyClaims Provide Initial Protection for Incysus’ Novel DRI PlatformIncysus Controls Exclusive...
Incysus Therapeutics to Present at Jefferies 2019 Global Healthcare Conference
22 mai 2019 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, May 22, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...